Another Alzheimer’s drug: what you need to know about donanemab’s promising trial results
American pharmaceutical company Eli Lilly announced recently that it had seen encouraging clinical trial results of its new Alzheimer’s medication.
According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%.
